biostudies-literatureUnknown28(17)Palazon-Carrion N<h4>Purpose</h4>New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma.<h4>Patients and methods</h4>In the phase II R2-GDP trial, 78 patients unsuitable for autologous stem cell transplant received treatment with the following schedule: lenalidomide 10 mg Days (D)1-14, rituximab 375 mg/m2 D1, cisplatin 60 mg/m2 D1, gemcitabine 750 mg/m2 D1 and D8, and dexamethasone 20 mg D1-3, up to 6 cycles (induction phase), followed by lenalidomide 10 mg (or last lenalidomide dose received) D1-21 every 28 days (maintenance phase). Primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and monitoClinical cancer research : an official journal of the American Association for Cancer Research3658-3668https://www.ebi.ac.uk/biostudies/studies/S-EPMC9433956biostudies-literatureLenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.PMC9433956de la Cruz-Vicente FGuirado-Risueno MEspejo-Garcia PHontecillas-Prieto LJimenez-Cortegana CGalvez-Carvajal LRueda-Dominguez ASanchez-Beato MNavarro MFernandez-Roman IGomez-Codina JRios-Herranz EPalazon-Carrion NGarcia-Dominguez DJSanchez-Margalet VMartin Garcia-Sancho ASalar-Silvestre ALabrador JRodriguez-Garcia GNogales-Fernandez ERodriguez-Abreu DFernandez-Alvarez RAlvaro-Naranjo Tde la Cruz-Merino LProvencio-Pulla MGuma-Padro JCarnicero-Gonzalez FMartinez-Banaclocha NCasanova-Espinosa MMarylene LfalseLenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.<h4>Purpose</h4>New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma.<h4>Patients and methods</h4>In the phase II R2-GDP trial, 78 patients unsuitable for autologous stem cell transplant received treatment with the following schedule: lenalidomide 10 mg Days (D)1-14, rituximab 375 mg/m2 D1, cisplatin 60 mg/m2 D1, gemcitabine 750 mg/m2 D1 and D8, and dexamethasone 20 mg D1-3, up to 6 cycles (induction phase), followed by lenalidomide 10 mg (or last lenalidomide dose received) D1-21 every 28 days (maintenance phase). Primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and monito2022-01-01T00:00:00Z2022 Sep2026-05-28T03:45:57.361Z2025-04-06T00:51:45.978ZS-EPMC94339563572760110.1158/1078-0432.CCR-22-0588